Ligong Lu

机构：Jinan University, Jimei University, Dongguan University of Technology, Chinese Academy of Geological Sciences, Guangxi Academy of Special Crops, Children's Hospital Colorado, Zhuhai People's Hospital, Guangzhou First People's Hospital, First People's Hospital of Chongqing, South China University of Technology, Guangzhou Medical University, University of Colorado Denver · ORCID：0000-0003-1405-0052

发表论文 305 篇 · 总被引 12513 次 · h-index 55

代表论文

• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025 · The Lancet · 被引 294)
• Integrating spatial and single-cell transcriptomics reveals tumor heterogeneity and intercellular networks in colorectal cancer (2024 · Cell Death and Disease · 被引 93)
• Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy (2024 · Liver International · 被引 87)
• High Intensity Focused Ultrasound‐Driven Nanomotor for Effective Ferroptosis‐Immunotherapy of TNBC (2024 · Advanced Science · 被引 59)
• Progress and Challenges in Tumor Ferroptosis Treatment Strategies: A Comprehensive Review of Metal Complexes and Nanomedicine (2024 · Small · 被引 56)
• Designing Bimetallic Metal‐Organic Framework‐Based Heterojunction Radiosensitizer for Enhanced Radiodynamic Therapy and Immunotherapy (2023 · Advanced Functional Materials · 被引 35)